Cerebral palsy is a condition that results from injuries or abnormalities of the brain, usually in the womb but occurring any time during 2 years after birth. It impairs brain functions such as thinking, seeing, hearing, learning and movement. The main causes are hypoxia (low oxygen levels), head injury, maternal infections such as rubella, brain bleeding, brain infection, and severe jaundice.

Mesenchymal stem cells from umbilical cord are considered to be universal donor cells because they are least antigenic and hence are not recognised as foreign cells. The cells home to damaged tissue and are known to secrete molecules called growth factors.

These factors from mesenchymal stem cells are known to stimulate repair of damaged nervous tissue in both the brain and the spinal cord.

Some of these are neural growth factors promote neuronal growth, induce new blood vessel formation, neurogenesis and astroglial activation, encourage synaptic connection and axonal remyelination, decrease programed cell death, and regulate microglial activation. These stem cells stimulate brain repair after stroke and traumatic brain injury.

Because we utilize allogeneic cord tissue-derived mesenchymal stem cells, we are able to offer treatment to patients.

There is also evidence to support that autologous bone marrow-derived mononuclear cells are safe and improve the quality of life in children with neurological disorders including cerebral palsy.

Stem cell Therapy for Cerebral palsy

Adult stem cells from human umbilical cord tissue are used to treat cerebral palsy. Umbilical cords are donated by mothers after normal, healthy births. In accordance with International Blood Bank standards, all umbilical cord-derived stem cells are rigorously screened for viruses and bacteria before they are approved for use in patients.

In some cases, stem cells harvested from the patient’s own bone marrow are also used in addition to umbilical cord tissue-derived cells.


The body’s immune system is unable to recognize umbilical cord-derived mesenchymal stem cells as foreign and therefore they are not rejected. We’ve treated hundreds of patients with umbilical cord stem cells and there has never been a single instance rejection (graft vs. host disease). Human umbilical cord tissue stem cells can also be expanded in the laboratory more easily than old bone marrow or adipose derived stem cells, hence they are considered to be more “potent”.

Protocol of treatment

Below is an example of a typical cerebral palsy protocol:

  • Treatment length (Monday – Friday): 5 Days
  • Four intravenous infusions of human umbilical cord tissue-derived allogeneic mesenchymal stem cells or bone marrow derived stem cells.
  • A qualified physician administers the stem cells intravenously (IV).

Our primary concern is to ensure each patient’s safety and proper follow-up plays an essential role in that process. Regular follow-up also enables us to evaluate efficacy and improve treatment protocols based on observed outcomes.

Therefore, our medical staff will be contacting you after 1 month, 3 months, 4 months, and 1 year to monitor your child’s progress.

Your Name (required)

Your Email (required)

Phone (required)


Your Message